7 unknown. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 1 | 1 | Unknown 1 |
Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer LM-108 antibody and sintilimab, LM-108 antibody and sintilimab and chemotherapy - NSCLC, PD-1 | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 50 | 2024-01-12 | 2024-06-28 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) F520, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer, NSCLC | Phase 2 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 84 | 2023-03-01 | 2023-02-24 |
| A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinomaļ¼The POTENTIAL Study Tislelizumab - Head and Neck Cancer, Radiation | Phase 2 | Unknown | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 38 | 2021-04-01 | 2021-03-24 |
| Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction PD-1inhibitor - PD-1, Neoadjuvant Chemoradiotherapy | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 32 | 2021-03-30 | 2024-02-09 |
| PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC PD-1 plus Dasatinib - NSCLC Stage IV, ARID1A | Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2020-03-01 | 2020-02-25 |
| Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ PD-1 - PD-1, Chemoradiotherapy | Phase 1 / Phase 2 | Unknown | Peking University | 45 | 2019-08-26 | 2019-08-20 |
Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
toripalimab (2) · Carboplatin (1) · Dasatinib (1) · Drug Therapy (1) · Paclitaxel (1) · Pemetrexed (1) · RC48 antibody (1) · disitamab vedotin (1) · sintilimab (1) · tislelizumab (1)
Peking University (1) · RenJi Hospital (1) · Shandong New Time Pharmaceutical Co., LTD (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · The Affiliated Hospital of Qingdao University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (5)
Chunxia Su, Phd (1) · Haige Chen (1) · Yongheng Li, MD (1) · Ziyu Li, MD (1)